Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical ...

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious ...

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...

Shares of Moderna ( MRNA) were up nearly 7% in recent trading, following a 12% jump Friday, after Bloomberg reported the ...

Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial ...

The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part of a ...

March 4 (Reuters) - Moderna shares rose ⁠9% ⁠on Wednesday after it settled ⁠a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing ...

Jan 22 (Reuters) - Moderna does ‌not plan to ‌invest in new late-stage vaccine trials because of growing opposition to ‍immunizations from U.S. officials, CEO Stephane Bancel said ⁠in an interview ...

Moderna shares jump as it reveals it has been researching vaccines against hantaviruses - The hantavirus outbreak on the MV ...

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...